Tweet
I was wondering if there has been any updated information on taking Ubrelvy while breastfeeding a newborn?
-
-
mhowe10325,
Here is the only data we have on Ubrelvy: Clinical Recommendation: "Urogepant is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. No breastfeeding data are presently available. However, it has high protein binding (87%), and is rather large in molecular weight. We anticipate that levels in milk will be low. In addition, the side effect profile of many these CGRP drugs is apparently quite low. Compared to the older family of triptans, sumatriptan and almotriptan, the CRGP antagonists are better tolerated with fewer side effects." InfantRisk Center database, Dr Thomas Hale, Dr kaytlin Krutsch.
We do have some data on Nurtec : "In a new clinical trial with 12 breastfeeding mothers 18-40 years, plasma and breastmilk samples were collected over a 36 hour period.[2] Rimagepant levels in breast milk and plasma were determined. Subjects (N=12) had a mean±SD age of 29.8±3.6 years and body mass index of 26.8±4.9 kg/m2. The mean±SD relative infant dose was 0.51±0.14%; the median (range) was 0.46% (0.36, 0.77). The mean±SD body-weight normalized infant dose was 0.005±0.001 mg/kg/day, body-weight normalized maternal dose was 1.04±0.18 mg/kg/day, and maternal body weight was 74.0±13.3 kg. On a weight-adjusted basis, infants received an estimated dose that was approximately 0.51% of the maternal dose.
Clinical Recommendation: Rimegepant is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. Levels in one study were exceedingly low with an RID of only 0.51%. Should be safe to use in breastfeeding mothers." InfantRisk Center database, Dr Thomas Hale, Dr kaytlin Krutsch.
The most common side effects with these types of medications to monitor your infant for would be GI upset, and dry mouth. Hope this helps.
Sandra Lovato R.N.
InfantRisk Center
Comment